Roche to complete $1.5 billion acquisition of U.S. biopharma company Poseida
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 08 2025
0mins
Source: Reuters
Roche's Acquisition of Poseida Therapeutics: Roche plans to complete its acquisition of U.S. biopharmaceutical company Poseida Therapeutics for approximately $1.5 billion, having accepted nearly 65 million shares, which represents 66% of Poseida's stock.
Strategic Expansion in Cancer Treatment: The acquisition will enhance Roche's development pipeline by adding allogeneic CAR-T cell therapies aimed at treating various blood cancers and autoimmune diseases, as Poseida becomes a wholly owned subsidiary.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
